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Abstract. The objective of this study is to optimize the tyrosinase inhibition effects of 
three mixtures included Emblica extract, L-Ascorbic acid, and Kojic acid. Tyrosinase is a 
copper-containing oxidase, which has activity for both catechol and cresol. It is 
responsible for browning reactions. Mushroom tyrosinase was used in this study as the 
tyrosinase source and L-DOPA was used to activate the browning activity. The seventeen 
formulations were conducted by extreme vertices mixture design. To specify the lower and 
upper limit, prior study for each ingredient was experimented. Ten and thirty-three 
percentage of inhibition were proposed to specify the lower and upper limit of each 
ingredient. The result of experiment shown the difference tyrosinase inhibition effects of 
seventeen formulations. The analysis of variance for result was significant for all pairs and 
all of components with 92.89 percentage of R-square adjusted. To optimize the best 
combination, used of response optimization by setting up the target to 80, 85, 90, and 95 
percentage of tyrosinase inhibition effect. The optimum combination with 90%inhibition 
target is 3.1541 mg./ml. of Emblica extract, 0.1420 mg./ml. of L-Ascorbic acid, and 0.0297 
mg./ml. of Kojic acid, this formula unlike the formula that was experimented on. 
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1. Introduction 
 
Concentrating on personal health and well-being has become a main objective for people living in wealthy 
societies, one of the world megatrend [1]. Wellness areas not only to have a healthy body but also to have a 
healthy mind, the skincare, massage, spa, salon, gym, and yoga are a part of wellness way [2]. Skin whitening 
is a sub-group of skincare products refers to the practice of using natural or synthetic substances to 
lighten the skin tone or reducing the melanin concentration in the skin [3]. Skin whitening products 
account for more than 60% of Thailand’s annual US$100 million facialskincare market [4]. Although most 
of the raw materials used in the production, imported from abroad. Most local cosmetic raw materials are 
inefficient enough to compete with foreign raw materials like the materials from Japan [5]. This research is 
aimed to development of raw materials for cosmetic skin care extracted from local natural sources to be 
effective equivalent to raw materials imported from abroad. The concept is to use synthetic substances used 
in high-performance skin care products to enhance the effect of natural extracts [6].  
In this research was chosen to develop the natural raw materials from Emblica extract, and 
synergistically with synthetic substances from the L-Ascorbic acid and Kojic acid [7]. Emblica extract or a 
Phyllanthus extract, used for topical cosmetic applications, particularly to lighten skin [8]. Phyllanthus 
emblica contain of many phenolic compounds include gallic acid and ellergic acid [9]. Gallic acid was 
oxidized by tyrosinase as substrates, yielding yellow oxidation products, but the long alkyl (>C 0) chain 
esters inhibited the enzyme with- out producing the pigmented products, indicating that the carbon chain 
length was related to their tyrosinase inhibitory activity [10]. The skin lightening effects of ellergic acid may 
due to chelating copper at the active site of tyrosinase to reduce its activity and inhibition of proliferation of 
melanocytes and melanin synthesis [11]. Vitamin C, or L-ascorbic acid, is the most abundant antioxidant in 
skin and used for skin lightening agent for many years [12]. For Kojic acid, it is used in cosmetics for its 
excellent whitening effect, inhibits catecholase activity of tyrosinase in a non-classical manner [13]. By 
performing tests on the inhibition of enzyme tyrosinase that it is a process to synthesize skin pigmentation 
or melanin. Melanins high molecular weight brown-pigments are synthesized by polymerization of quinine 
because of their high reactivity and react with amino acids and proteins to enhance brown color of the 
pigment [14]. In vitro test, modified L-DOPA was used to evaluate the performance of each combination. 
Minitab17 was used for planning the experiments, data analysis, contour diagrams and response 
optimizations. The extreme vertices designs, the measures response is assumed to depend on only the 
proportions of the ingredients present in the mixture and not on the amount of the mixture [15]. Like this 
experimental, the amount of three combination; Emblica extract, L-Ascorbic acid, and Kojic acid, up to 4 
mg./ml. in phosphate solution or 0.4% in the whole of formulation. After experiment, Minitab software will 
create a regression equation that can predict the response result [16]. Because experimental formula may not 
be the best formula yet. The final decision may be determined by the cost factor of the raw materials 
involved. Because of the diversity of situations in which multi-objective decision problems can arise and 
because of the multiplicity of factors that are involved [17]. 
 
2. Tyrosinase Inhibition Experiments  
 
Nowadays mushroom tyrosinase has become popular because it is readily available and useful in a number 
of applications [18]. Mushroom Tyrosinase was used in this study as the Tyrosinase source. Briefly, 40 l of 
aqueous solution of mushroom Tyrosinase (480 units/ml) was added to a 96-wellmicor-plate, in a total 
volume of 520 ml. assay mixture containing 40 l. (0.16 mg./ml) of L-DOPA solution, and 20 mM 
phosphate buffer (pH 6.5). The assay mixture was incubated at 25 °C for 20 min. Following incubation, 
dopachrome produced in the reaction mixture was deter-mined spectrophotometrically at 492 nm. in a 
micro-plate reader. 
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Fig. 1. 96-wellmicro-plate. 
 
Figure 1 shows zone A, B, C, and D, zone A are the mixture of solvent, buffer, Tyrosinase, and L-
DOPA. Zone B are the mixture of solvent, buffer, and L-DOPA. Zone C are the mixture of active 
ingredients, buffer, Tyrosinase, and L-DOPA. Zone D are the mixture of active ingredients, buffer, and L-
DOPA. Every zone, 6 replicates on rows were conducted. After deter-mined by spectrophotometrically, the 
percentage of inhibition were calculated by the following equation. 
 
 %Inhibition = (C-D) / (A-B)  (1) 
 
The individual agent was prior study to explore the amount of each and to specify the upper and lower 
bound. The 33.33% inhibition was selected as upper bound (because total of three upper bound should not 
be over 100%) and 10% inhibition was selected as lower bound of each agent. Calculated by below 
equations that it analyzed from Microsoft Excel. 
 
 
 
Fig. 2. Emblica Extract individual test. (Conc.=Concentration mg./ml.) 
 
From Fig. 2, Emblica Extract inhibition equation with R² = 0.95794 is: 
 
 y = -0.278x2 + 10.704x - 2.9767 (2) 
 
Thus, if x = 33.34%inhibiton then y = 3.76 mg./ml., if x = 10%inhibiton then y = 1.26 mg./ml. 
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Fig. 3. L-Ascorbic acid individual test. (Conc.=Concentration g./ml.) 
 
From Fig. 3, L-Ascorbic acid inhibition equation with R² = 0.97128 is: 
 
 y = -6E-06x3 + 0.0037x2 - 0.2869x + 9.9121 (3) 
 
Thus, if x = 33.34%inhibiton then y = 0.158 mg./ml., if x = 10%inhibiton then y = 0.092 mg./ml. 
 
 
 
Fig. 4. Kojic acid individual test. (Conc.=Concentration g./ml.) 
 
From Fig. 4, Kojic acid inhibition equation with R² = 0.99942is: 
 
 y = 5E-10x5 - 5E-07x4 + 0.0001x3 - 0.0232x2 + 2.0725x - 14.307 (4) 
 
Thus, if x = 33.34%inhibiton then y = 0.035 mg./ml., if x = 10%inhibiton then y = 0.014 mg./ml. 
 
From above equations, the upper bound and the lower bound of each ingredient were calculated that 
shown on Table 1. 
 
Table 1. Upper and lower bound for mixture design. 
 
Agents Inhibtion Emblica Extract L-Ascorbic acid  Kojic Acid 
Upper Bound 33.33% 3.76 mg./ml. 0.158 mg./ml. 0.035 mg./ml. 
Lower Bound 10% 1.26 mg./ml. 0.092 mg./ml. 0.014 mg./ml. 
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3. Extreme Vertices Design 
 
Mixture experiments are a special class of response surface experiments in which the product under 
investigation is made up of several components or ingredients [19]. Designs for these experiments are useful 
because many product design and development activities in industrial situations involve formulations or 
mixtures. Extreme vertices designs are mixture designs that cover only a sub-portion or smaller space 
within the simplex. These designs must be used when your chosen design space is not an L-simplex design. 
The presence of both lower and upper bound constraints on the components often create this condition. 
The goal of an extreme vertices design is to choose design points that adequately cover the design space 
[20].  
 
Table 2. Experiments result. 
 
Formula Emblica (A) Vit.C (B) Kojic (C) Buffer (D) % Inhibition 
1 3.76 0.158 0.035 996.047 96.28619287 
2 3.76 0.092 0.035 996.113 92.16080402 
3 1.885 0.1085 0.01925 997.98725 70.13161043 
4 1.26 0.158 0.014 998.568 73.15147164 
5 1.26 0.158 0.035 998.547 94.35271596 
6 1.885 0.1415 0.01925 997.95425 73.09882747 
7 2.51 0.125 0.0245 997.3405 80.36850921 
8 3.135 0.1415 0.02975 996.69375 90.44268964 
9 3.76 0.158 0.014 996.068 83.68987796 
10 1.885 0.1415 0.02975 997.94375 84.60397224 
11 3.76 0.092 0.014 996.134 72.66331658 
12 3.135 0.1415 0.01925 996.70425 81.76118689 
13 3.135 0.1085 0.01925 996.73725 79.01411821 
14 3.135 0.1415 0.02975 996.69375 87.98755683 
15 1.26 0.092 0.014 998.634 56.29576454 
16 1.885 0.1085 0.02975 997.97675 83.2160804 
17 1.26 0.092 0.035 998.613 80.54079923 
18 2.51 0.092 0.0308 997.3672 81.90954774 
19 1.7 0.157 0.02952 998.11348 91.63436229 
 
The Minitab software generated 17 different combinations of Emblica Extract, L-Ascorbic acid, and 
Kojic acid. The results of 17 formula were illustrated on the Table 2. The combinations had inhibited effect 
between 56.29% to 96.28%. This result referred to maximum and minimum of ingredients usage. The 
maximum used should be inhibited 100% but it had only 96.9% (formula1). On the other hand, the 
minimum used should be inhibited 30% but it had 56.29% (formula15).  
The result of analysis with Minitab17 shown the ANOVA table for %inhibition in the Table 3 with R-
square adjusted 92.89% regression coefficients for %inhibition. By set up analysis criteria as DOE>Mixture 
Design>Analysis components in Proportions>Terms A, B, C, D, AB, AC, AD, BC, ABC, ABD, ACD, 
BCD. Where A=Emblica Extract, B=L-Ascorbic acid, C=Kojic acid, D=Phosphate buffer. 
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Fig. 5. Residual Plots for %inhibition. 
 
Figure 5 shows 4 in 1 residual plots for % inhibition. The normal probability plot, versus fits, histogram, 
and versus order explained normal distribution of the data. 
 
Table 3. Analysis of Variance for %Inhibition. (component proportions). 
 
Source                            DF   Seq SS   Adj SS   Adj MS       F      P 
Regression                        11   9768.2  9768.22  888.020  121.00  0.000 
   Linear                          3   9053.7   380.36  126.788   17.28  0.000 
   Quadratic                       4    451.8   248.73   62.181    8.47  0.000 
     Emblica *L-Ascorb             1    195.3    33.00   32.997    4.50  0.037 
     Emblica *Kojic ai             1    162.8    42.81   42.807    5.83  0.018 
     Emblica *Phosphat             1      0.0    51.96   51.963    7.08  0.009 
     L-Ascorb*Kojic ai             1     93.7    42.22   42.221    5.75  0.019 
   Special Cubic                   4    262.8   262.75   65.688    8.95  0.000 
     Emblica *L-Ascorb*Kojic ai    1     14.0    42.23   42.229    5.75  0.019 
     Emblica *L-Ascorb*Phosphat    1    199.1    33.00   32.996    4.50  0.037 
     Emblica *Kojic ai*Phosphat    1      7.5    42.81   42.808    5.83  0.018 
     L-Ascorb*Kojic ai*Phosphat    1     42.2    42.22   42.221    5.75  0.019 
Residual Error                    90    660.5   660.49    7.339 
   Lack-of-Fit                     5     33.9    33.90    6.781    0.92  0.472 
   Pure Error                     85    626.6   626.59    7.372 
Total                            101  10428.7 
 
Table 3 illustrates the analysis of variance for %inhibition effect. P-value of all combination terms were 
more than 0.05 that there were significant at 95% confidence level. Although, for AB (Emblica and L-
Ascorbic acid) and ABD (Emblica and L-Ascorbic acid and Phosphate buffer were nearly 0.05 of P-value. 
For residual error term shown lack-of-fit was not significant at 0.472 that means no more term of 
combination need to analyze.  
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Table 4. Estimated Regression Coefficients for %Inhibition (component proportions). 
 
Term VIF  Coef SE Coef T P 
Emblica Extract 1333835097 -9719791 3646008 * * 
L-Ascorbic acid 207152 3145188 957240 * * 
Kojic acid 30041144 164621081 68205929 * * 
Phosphate Buffer5620 -45 20 * * 
Emblica Extract*L-Ascorbic acid 
2.96992E+11 
-9.03533E+11 4.26109E+11 -2.12 0.037 
Emblica Extract*Kojic acid 
1.18921E+12 
-1.01673E+13 4.20975E+12 -2.42 0.018 
Emblica Extract*Phosphate Buffer 
1341015933 
9760071 3667907 2.66 0.009 
L-Ascorbic acid*Kojic acid 
5.54788E+15 
1.45573E+16 6.06911E+15 2.40 0.019 
Emblica Extract*L-Ascorbic acid* 
40323901236 Kojic acid 
-1.45517E+16 6.06627E+15 -2.40 0.019 
Emblica Extract*L-Ascorbic acid* 
2.98157E+11Phosphate Buffer 
9.08312E+11 4.28365E+11 2.12 0.037 
Emblica Extract*Kojic acid* 
1.19338E+12Phosphate Buffer 
1.02191E+13 4.23119E+12 2.42 0.018 
L-Ascorbic acid*Kojic acid* 
5.52155E+15Phosphate Buffer 
-1.45616E+16 6.07093E+15 -2.40 0.019 
S = 2.70902 PRESS = 833.125  
R-Sq = 93.67% R-Sq(pred) = 92.01% R-Sq(adj) = 92.89% 
 
 
Table 4 illustrated the estimated regression coefficients for %inhibition effect with 2.70902 standard 
error and R-square predict was 92.01%. This regression model was used to predict the %inhibition effect by 
vary the amount of each ingredients and used in the algorithm for optimization process. 
 
 
 
Fig. 6. Overlaid contour plot of % inhibition. 
 
Figure 6 shows the overlaid contour plot of %inhibition, setting up the feasible area for 50 to 100% 
inhibition effect. Because of the data in Table 2 indicating the range between 56.29% to 96.28%, the white 
area in the figure is the possible area for the combinations that can make 50 to 100% inhibition effect. 
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Fig. 7. Contour plot of % inhibition. 
 
Figure 7 shows the contour plot of %inhibition, separated feasible area to 5 ranges for inhibition effect, 
less than 10%, 10% to 50%, 50% to 80%, 80% to 100%, and more than 100%. This plot make contrast 
from Fig. 6. The darkest area is impossible area (more than 100%) and lighter area is possible area for each 
range.  
 
4. Optimization the Tyrosinase Inhibition Effects 
 
Consider Fig. 8 that shows optimization result; set it to the maximum value. Dotted horizontal line is a line 
that cuts through every ingredient in the recipe. For vertical solid lines of three inhibitors that this 
concentration is required only to get the desired result. For the solid line of Phosphate buffer, more the 
volume increases, it will tend to decrease inhibition effect. Software predicts the value of the component 
that is used most. And the results close to the real experiment (formula1) result on the Table 2. 
 
 
 
Fig. 8. Optimization the tyrosinase inhibition effect with maximum target. 
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Therefore, in setting the goal of this experiment should be more than 80% inhibition, so set to optimize 
with the target of 80%, 85%, 90%, 95%, and Max%. Then compare the values to make the decision to 
choose the best formula. Figure 9 is an example of optimization at the target of 90%. 
 
 
 
Fig. 9. Optimization the tyrosinase inhibition effect with 90% target. 
 
Consider Fig. 9 that shows optimization result; set it to 90% inhibition effect. Dotted horizontal line is 
a line that cuts through every ingredient in the recipe like Fig. 8. But the solid lines of three inhibitors were 
different from Fig. 8. For the solid line of Emblica extract and Phosphate buffer, more the volume 
increases, it will tend to decrease inhibition effect. On the other hand, the solod line of L-Ascorbic acid and 
Kojic acid, more the volume increases, it will tend to increase inhibition effect too. 
 
Table 5. Optimization the tyrosinase inhibition effect with target of 80%, 85%, 90%, 95%, and Max%. 
 
Reponse 80% 85% 90%  95% 100% 
Predicted 80.0000 85.0000 89.9822 94.9992 96.2059 
Emblica 1.2600 2.5100 3.1541 3.6070 3.7600 
L-Ascorbic 0.1250 0.1250 0.1420 0.1554 0.1580 
Kojic acid 0.0284 0.0286 0.0297 0.0337 0.0350 
 
Table 5 shows the result from Optimization the tyrosinase inhibition effect with target of 80%, 85%, 
90%, 95%, and Max%. Of course, the more effective formula, the higher cost of raw materials, as well. 
Figure 10 illustrated the multiple choice can be used for decision support data. 
 
 
 
Fig. 10. Multiple choice for decision making. 
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5. Conclusion and Discussion 
 
This study aim to test the efficacy of three types of whitening compounds, Emblica, L-Ascorbic acid, and 
Kojic acid, by designing an extreme lactices mixture design, suitable for chemical ingredients, which could 
not calculate the reaction to each other. The results show that the proportion of different ingredients is 
effective for different inhibition tyrosinase. The results of the contour plot show that the formula for each 
performance level can make a variety of formulas on possible graph areas. So, choosing the most 
appropriate formulas by Minitab17 optimizer can be found using the costing calculator to make that 
decision support need of performance at any level. Because, based on the graphs in the single-agent test, 
80% of the inhibit level is linear. It means that if it is over 80%, the concentration increase will start to slow 
down. For the conclusion, middle target of 90%inhibtion effect was selected. The optimum combination is 
3.1541 mg./ml. of Emblica extract, 0.1420 mg./ml. of L-Ascorbic acid, and 0.0297 mg./ml. of Kojic acid, 
This research will not only to test the efficiency of raw materials but also to development of natural 
ingredients to be as effective as synthetic materials. Contribution from this research will guide researchers to 
develop new raw materials from nature by using extreme vertices mixture design. The benefits of this 
technique are make reduce time and saving experiment cost. For the further research, the other 
optimization techniques can be applied for the optimization process. Like this study, the Minitab optimizer 
could not be calculated the multi-objective task. The solution may be fall in local result (consider wide area 
on contour plot). Evolutional programing such as Genetic Algorithm, Particle Swarm, or other meta 
heuristic may be apply for this project, to make decision both effective and value altogether. 
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